liver cancer

Pharma

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Following resolution of the problem cited in the CRL, investors questioned why the FDA issued a swift rejection instead of waiting for the PDUFA date.

Angus Liu Jul 28, 2026 3:02pm

AZ's Imfinzi, Imjudo combo polishes case in early liver cancer

Jun 1, 2026 8:24am

Another AstraZeneca Emerald glimmers in liver cancer

Apr 2, 2026 10:12am

Golfer devastated after just barely missing a putt

Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type

Oct 29, 2025 11:32am

BMS follows Roche, AstraZeneca into first-line liver cancer

Apr 11, 2025 1:53pm

FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again

Mar 21, 2025 3:25pm